Related Posts
Incannex Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment
Nyrada Inc – CEO Remuneration Update
Interview with Canary Capital’s Paul Hart
